Global Substance Abuse (Alcohol, Cocaine, Marijuana, Nicotine) Treatment Market Report 2024-2030: Emerging Trends and Regional Insights for Products and Treatment Options
29 janv. 2024 09h07 HE
|
Research and Markets
Dublin, Jan. 29, 2024 (GLOBE NEWSWIRE) -- The "Global Substance Abuse Treatment Market by Substance Abuse Type (Alcohol Addiction, Cocaine, Marijuana), Product (Behavioral Treatment, Drugs),...
Global Substance Abuse Treatment Market Review and Forecast to 2030: Alcohol Addiction Commanded the Largest Market Share of 34.27% in 2022, Followed by Nicotine Addiction
09 juin 2023 07h23 HE
|
Research and Markets
Dublin, June 09, 2023 (GLOBE NEWSWIRE) -- The "Global Substance Abuse Treatment Market by Substance Abuse Type (Alcohol Addiction, Cocaine, Marijuana), Product (Behavioral Treatment, Drugs),...
U.S. Substance Abuse Treatment Market Report 2023: Surging Rate of Drug Addiction and the Growing Prevalence of Alcohol and Smoking Among Teenagers Drives Growth
17 avr. 2023 07h43 HE
|
Research and Markets
Dublin, April 17, 2023 (GLOBE NEWSWIRE) -- The "Substance Abuse Treatment Market Research Report by Substance Abuse Type (Alcohol Addiction, Cocaine, Marijuana), Product (Behavioral Treatment,...
InvestmentPitch Media Video Discusses LOVE Pharma’s Plans to Continue Developing a Portfolio of Innovative Products such as Naltrexone Encompassing Transdermal Drug Delivery Applications for Addictions and Long-COVID
07 nov. 2022 06h00 HE
|
InvestmentPitch Media and Love Pharma Inc
VANCOUVER, British Columbia, Nov. 07, 2022 (GLOBE NEWSWIRE) -- LOVE Pharma (CSE:LUV) (FSE:G1Q0) continues with its plans to develop a portfolio of innovative products encompassing transdermal drug...
Acquisition Has Love Pharma’s Naltrexone on NIH Shortlist to Address Unmet Medical Need—Treatment for Long Covid
03 nov. 2022 08h45 HE
|
Love Pharma Inc.
NEW YORK, NY, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Love Pharma Inc. (CSE: LUV) (FSE: G1Q0), an international mental health and sexual wellness company, has been explicit about its plans to develop a...
InvestmentPitch Media Video Discusses LOVE Pharma’s Pending Acquisition of Naltrexone Therapeutics Supported by Reports that Naltrexone Demonstrates Promising Long COVID Applications
21 oct. 2022 06h00 HE
|
InvestmentPitch Media and Love Pharma Inc
VANCOUVER, British Columbia, Oct. 21, 2022 (GLOBE NEWSWIRE) -- LOVE Pharma (CSE:LUV) (FSE:G1Q0) which on October 11th signed a nonbinding Letter of Intent to acquire 100% of Naltrexone Therapeutics,...
North America Addictions Therapeutics Market Report 2020-2027: Focus on Nicotine, Alcohol & Opioid Addiction Treatment
22 janv. 2021 08h08 HE
|
Research and Markets
Dublin, Jan. 22, 2021 (GLOBE NEWSWIRE) -- The "North America Addictions Therapeutics Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Treatment Type; Drug Type; Treatment Center;...
BioCorRx’s Director Louis Lucido Appeared Today on Yahoo Finance LIVE “On the Move”
22 juil. 2019 14h03 HE
|
BioCorRx Inc
ANAHEIM, CA, July 22, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a leader, developer and provider of advanced solutions in the treatment of addiction...
BioCorRx’s Subsidiary, BioCorRx Pharmaceuticals, to Exhibit at ASAM 50th Annual Conference in Orlando, Florida
28 mars 2019 08h00 HE
|
BioCorRx Inc
ANAHEIM, CA, March 28, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the “Company), a developer and provider of advanced solutions in the treatment of substance abuse...
BioCorRx Announces Formation of Scientific Advisory Board
19 févr. 2019 10h26 HE
|
BioCorRx Inc
ANAHEIM, CA, Feb. 19, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use...